CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that Michael Bonney, current Board member and former chief executive of Cubist Pharmaceuticals, has been appointed as Chairman effective January 1, 2016. Founding investor and current Chairman John Clarke will remain on the Board as a Director. Alnylam also announced today that David Pyott has been elected to the company’s Board. Mr. Pyott is former chairman and Chief Executive Officer of Allergan and will join the Alnylam Board effective immediately.
